A population-based analysis on the use of therapeutic plasma exchange and intravenous immunoglobulin in heparin-induced thrombocytopenia.
| dc.contributor.author | Soares Ferreira JĂșnior, Alexandre | |
| dc.contributor.author | Boyle, Stephen H | |
| dc.contributor.author | Kuchibhatla, Maragatha | |
| dc.contributor.author | Onwuemene, Oluwatoyosi A | |
| dc.date.accessioned | 2023-04-07T13:11:52Z | |
| dc.date.available | 2023-04-07T13:11:52Z | |
| dc.date.issued | 2021-05 | |
| dc.date.updated | 2023-04-07T13:11:52Z | |
| dc.description.abstract | IntroductionIn heparin-induced thrombocytopenia (HIT), selected patients are treated with therapies directed at the immune response, intravenous immunoglobulin (IVIG) and therapeutic plasma exchange (TPE). To determine IVIG and TPE characteristics and outcomes in HIT, we analyzed the National Inpatient Sample (NIS) database.MethodsIn a population-based analysis of the NIS, we identified hospital discharges of adult patients with a HIT diagnosis. A two-level statistical analysis was performed comparing cases as follows 1) IVIG or TPE vs. none; and 2) IVIG vs. TPE. For each analysis, the primary outcome was in-hospital mortality. Secondary outcomes were thrombotic events, major bleeding, infections, hospital length of stay, and total charges.ResultsAmong 22,152 discharges with a HIT diagnosis, 77 (0.34%) and 52 (0.23%) received TPE and IVIG, respectively. In the first level analysis of TPE or IVIG vs. no treatment, TPE or IVIG treatment was associated with a higher likelihood of in-hospital mortality (OR = 1.85; 95%CI: 1.13-3.03, p = 0.0104), major bleeding (OR = 1.91; 95%CI: 1.25-2.93, p = 0.0030), gastrointestinal bleeding (OR = 1.89; 95%CI: 1.08-3.30, p = 0.0259), and infection (OR = 1.65; 95% CI:1.13-2.41, p = 0.0095). In the second-level analysis comparing IVIG vs. TPE, there were no significant differences in patient characteristics or outcomes in both unadjusted and adjusted analyses.ConclusionsIn this population-based analysis of HIT, we found similar outcomes of IVIG and TPE-treated cases. Given the small sample size, future studies are needed to confirm this observation. | |
| dc.identifier | S0049-3848(21)00065-7 | |
| dc.identifier.issn | 0049-3848 | |
| dc.identifier.issn | 1879-2472 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.publisher | Elsevier BV | |
| dc.relation.ispartof | Thrombosis research | |
| dc.relation.isversionof | 10.1016/j.thromres.2021.02.017 | |
| dc.subject | Humans | |
| dc.subject | Thrombosis | |
| dc.subject | Thrombocytopenia | |
| dc.subject | Heparin | |
| dc.subject | Immunoglobulins, Intravenous | |
| dc.subject | Plasma Exchange | |
| dc.subject | Adult | |
| dc.title | A population-based analysis on the use of therapeutic plasma exchange and intravenous immunoglobulin in heparin-induced thrombocytopenia. | |
| dc.type | Journal article | |
| duke.contributor.orcid | Onwuemene, Oluwatoyosi A|0000-0001-7266-7101 | |
| pubs.begin-page | 6 | |
| pubs.end-page | 14 | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Staff | |
| pubs.organisational-group | Basic Science Departments | |
| pubs.organisational-group | Clinical Science Departments | |
| pubs.organisational-group | Institutes and Centers | |
| pubs.organisational-group | Biostatistics & Bioinformatics | |
| pubs.organisational-group | Medicine | |
| pubs.organisational-group | Psychiatry & Behavioral Sciences | |
| pubs.organisational-group | Medicine, Hematology | |
| pubs.organisational-group | Center for the Study of Aging and Human Development | |
| pubs.organisational-group | Psychiatry & Behavioral Sciences, Behavioral Medicine & Neurosciences | |
| pubs.publication-status | Published | |
| pubs.volume | 201 |
Files
Original bundle
- Name:
- TH Resubmission Clean Copy.docx
- Size:
- 109.49 KB
- Format:
- Unknown data format
- Description:
- Accepted version